Working… Menu

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02992522
Recruitment Status : Suspended (PI decsion)
First Posted : December 14, 2016
Last Update Posted : June 3, 2019
Genentech, Inc.
Information provided by (Responsible Party):
Beth Christian, Ohio State University Comprehensive Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : January 31, 2020
Estimated Study Completion Date : January 31, 2021